Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. STKE, 23 April 2002
Vol. 2002, Issue 129, p. re5
[DOI: 10.1126/stke.2002.129.re5]

REVIEWS

Endocannabinoids and Neuroprotection

R. Mechoulam1*, M. Spatz3, and E. Shohami2

1Department of Medicinal Chemistry and Natural Products, Hebrew University Medical Faculty, Jerusalem 91120, Israel.
2Department of Pharmacology, Hebrew University Medical Faculty, Jerusalem 91120, Israel.
3Stroke Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 36 Convent Drive, MSC 4128, Bethesda, MD 20892-4128, USA.

Abstract: Traumatic brain injury (TBI) releases harmful mediators that lead to secondary damage. On the other hand, neuroprotective mediators are also released, and the balance between these classes of mediators determines the final outcome after injury. Recently, it was shown that the endogenous brain cannabinoids anandamide and 2-Arachidonoyl glycerol (2-AG) are also formed after TBI in rat and mouse respectively, and when administered after TBI, they reduce brain damage. In the case of 2-AG, better results are seen when it is administered together with related fatty acid glycerol esters. Significant reduction of brain edema, better clinical recovery, and reduced infarct volume and hippocampal cell death are noted. This new neuroprotective mechanism may involve inhibition of transmitter release and of inflammatory response. 2-AG is also a potent modulator of vascular tone, and counteracts the endothelin (ET-1)-induced vasoconstriction that aggravates brain damage; it may thus help to restore blood supply to the injured brain.

*Corresponding author. E-mail: mechou{at}cc.huji.ac.il

Citation: R. Mechoulam, M. Spatz, E. Shohami, Endocannabinoids and Neuroprotection. Sci. STKE 2002, re5 (2002).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications.
L. K. Miller and L. A. Devi (2011)
Pharmacol. Rev. 63, 461-470
   Abstract »    Full Text »    PDF »
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
C. Blazquez, A. Chiarlone, O. Sagredo, T. Aguado, M. R. Pazos, E. Resel, J. Palazuelos, B. Julien, M. Salazar, C. Borner, et al. (2011)
Brain 134, 119-136
   Abstract »    Full Text »    PDF »
CB1 Cannabinoid Receptors Increase Neuronal Precursor Proliferation through AKT/Glycogen Synthase Kinase-3{beta}/{beta}-Catenin Signaling.
S. Trazzi, M. Steger, V. M. Mitrugno, R. Bartesaghi, and E. Ciani (2010)
J. Biol. Chem. 285, 10098-10109
   Abstract »    Full Text »    PDF »
NEUROSCIENCE: Stout Guards of the Central Nervous System.
R. Mechoulam and A. H. Lichtman (2003)
Science 302, 65-67
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882